289 related articles for article (PubMed ID: 25603286)
41. Riboswitches as Drug Targets for Antibiotics.
Panchal V; Brenk R
Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33466288
[TBL] [Abstract][Full Text] [Related]
42. Selective small-molecule inhibition of an RNA structural element.
Howe JA; Wang H; Fischmann TO; Balibar CJ; Xiao L; Galgoci AM; Malinverni JC; Mayhood T; Villafania A; Nahvi A; Murgolo N; Barbieri CM; Mann PA; Carr D; Xia E; Zuck P; Riley D; Painter RE; Walker SS; Sherborne B; de Jesus R; Pan W; Plotkin MA; Wu J; Rindgen D; Cummings J; Garlisi CG; Zhang R; Sheth PR; Gill CJ; Tang H; Roemer T
Nature; 2015 Oct; 526(7575):672-7. PubMed ID: 26416753
[TBL] [Abstract][Full Text] [Related]
43. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies.
Baquero F; Coque TM; Cantón R
Expert Opin Ther Targets; 2014 Aug; 18(8):851-61. PubMed ID: 24881465
[TBL] [Abstract][Full Text] [Related]
44. Multi-targeting by monotherapeutic antibacterials.
Silver LL
Nat Rev Drug Discov; 2007 Jan; 6(1):41-55. PubMed ID: 17159922
[TBL] [Abstract][Full Text] [Related]
45. New insights into riboswitch regulation mechanisms.
Bastet L; Dubé A; Massé E; Lafontaine DA
Mol Microbiol; 2011 Jun; 80(5):1148-54. PubMed ID: 21477128
[TBL] [Abstract][Full Text] [Related]
46. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time?
Vicente M; Hodgson J; Massidda O; Tonjum T; Henriques-Normark B; Ron EZ
FEMS Microbiol Rev; 2006 Nov; 30(6):841-52. PubMed ID: 17064283
[TBL] [Abstract][Full Text] [Related]
47. Drugs for bad bugs: confronting the challenges of antibacterial discovery.
Payne DJ; Gwynn MN; Holmes DJ; Pompliano DL
Nat Rev Drug Discov; 2007 Jan; 6(1):29-40. PubMed ID: 17159923
[TBL] [Abstract][Full Text] [Related]
48. Antisense RNA regulation and application in the development of novel antibiotics to combat multidrug resistant bacteria.
Ji Y; Lei T
Sci Prog; 2013; 96(Pt 1):43-60. PubMed ID: 23738437
[TBL] [Abstract][Full Text] [Related]
49. An engineered riboswitch as a potential gene-regulatory platform for reducing antibacterial drug resistance.
Feng X; Liu L; Duan X; Wang S
Chem Commun (Camb); 2011 Jan; 47(1):173-5. PubMed ID: 20589309
[TBL] [Abstract][Full Text] [Related]
50. Alternative natural sources for a new generation of antibacterial agents.
Taylor PW
Int J Antimicrob Agents; 2013 Sep; 42(3):195-201. PubMed ID: 23796893
[TBL] [Abstract][Full Text] [Related]
51. Riboswitch regulation of aminoglycoside resistance acetyl and adenyl transferases.
Jia X; Zhang J; Sun W; He W; Jiang H; Chen D; Murchie AI
Cell; 2013 Jun; 153(7):1419-20. PubMed ID: 23791168
[No Abstract] [Full Text] [Related]
52. [The search for novel antibiotics--strategies and current approaches].
Schmid P
Berl Munch Tierarztl Wochenschr; 2014; 127(11-12):498-512. PubMed ID: 25872259
[TBL] [Abstract][Full Text] [Related]
53. New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.
Klahn P; Brönstrup M
Curr Top Microbiol Immunol; 2016; 398():365-417. PubMed ID: 27704270
[TBL] [Abstract][Full Text] [Related]
54. Screening strategies for discovery of antibacterial natural products.
Singh SB; Young K; Miesel L
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):589-613. PubMed ID: 21819327
[TBL] [Abstract][Full Text] [Related]
55. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
Kim W; Hendricks GL; Lee K; Mylonakis E
Expert Opin Drug Discov; 2017 Jun; 12(6):625-633. PubMed ID: 28402221
[TBL] [Abstract][Full Text] [Related]
56. Bacterial resistance to cationic antimicrobial peptides.
Anaya-López JL; López-Meza JE; Ochoa-Zarzosa A
Crit Rev Microbiol; 2013 May; 39(2):180-95. PubMed ID: 22799636
[TBL] [Abstract][Full Text] [Related]
57. The relationship between target-class and the physicochemical properties of antibacterial drugs.
Mugumbate G; Overington JP
Bioorg Med Chem; 2015 Aug; 23(16):5218-24. PubMed ID: 25975639
[TBL] [Abstract][Full Text] [Related]
58. UDP-N-acetylglucosamine enolpyruvyl transferase as a potential target for antibacterial chemotherapy: recent developments.
Gautam A; Rishi P; Tewari R
Appl Microbiol Biotechnol; 2011 Oct; 92(2):211-25. PubMed ID: 21822642
[TBL] [Abstract][Full Text] [Related]
59. Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways.
Mulhbacher J; Brouillette E; Allard M; Fortier LC; Malouin F; Lafontaine DA
PLoS Pathog; 2010 Apr; 6(4):e1000865. PubMed ID: 20421948
[TBL] [Abstract][Full Text] [Related]
60. Novel target sites in bacteria for overcoming antibiotic resistance.
Black MT; Hodgson J
Adv Drug Deliv Rev; 2005 Jul; 57(10):1528-38. PubMed ID: 15949866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
